Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been used widely in clinical practice. Here, SLC5A2 is linked to type 2 diabetes mellitus.